DEPRESSIYA VA PSIXOTIK BUZILISHLARNI DAVOLASHDA FARMAKOLOGIK REZISTENTLIK: MUAMMOLAR VA YECHIMLAR
Keywords:
farmakologik rezistentlik, depressiya, psixotik buzilish, farmakogenetika, antipsixotik, antidepressant, komorbidlik.Abstract
Ushbu maqolada depressiya va psixotik buzilishlarni davolash jarayonida uchraydigan farmakologik rezistentlik (davolashga chidamlilik) holatlari tahlil qilinadi. Farmakodinamik va farmakokinetik omillar, genetik predispozitsiya, komorbid holatlar va individual javob farqlari sababli yuzaga keluvchi terapevtik samaradorlikning pastligi asosiy muammo sifatida ko‘rsatib o‘tilgan. Shuningdek, maqolada zamonaviy yondashuvlar – polimorfizmga asoslangan farmakogenetika, transkranial magnit stimulyatsiya, psixoterapevtik qo‘shma terapiyalar va yangi preparat sinflar orqali yechimlar taklif etiladi.
References
1. Rush A.J., Trivedi M.H., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.
2. Kirchheiner J., Nickchen K., Bauer M., et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9(5):442–473.
3. Meyer J.H., et al. Elevated monoamine oxidase A levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006;63(11):1209–1216.
4. Bauer M., Pfennig A., Severus E., et al. WFSBP guidelines for biological treatment of unipolar depressive disorders, part 1. World J Biol Psychiatry. 2013;14(5):334–385.
5. Lieberman J.A., Stroup T.S., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.
6. Phillips K.A., Veenstra D.L., et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001;286(18):2270–2279.
7. George M.S., Lisanby S.H., et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: A sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67(5):507–516.
8. Aan Het Rot M., Zarate C.A., et al. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012;72(7):537–547.
9. Dinan T.G., Stilling R.M., Stanton C., Cryan J.F. Collective unconscious: how gut microbes shape human behavior. J Psychiatr Res. 2015;63:1–9.
